Vcanbio Cell & Gene Engineering Corp Tax Expense
The Income Tax Expense of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 6, 2026 is 70.92 M CNY. In the previous year, Income Tax Expense was 46.59 M CNY — a change of 52.21% (higher).
Get this data via API
Financial Data API
Tax Expense
70.92 MCNY
YoY
52.21%
Last updated:
The Vcanbio Cell & Gene Engineering Corp Tax Expense history
3 Years
10 Years
25 Years
Max
| YEAR | Tax Expense | YoY |
|---|---|---|
| 70.92 MCNY | +52.21% | |
| 46.59 MCNY | +36.90% | |
| 34.03 MCNY | -29.86% | |
| 48.53 MCNY | -32.37% | |
| 71.75 MCNY | +89.66% | |
| 37.83 MCNY | -36.44% | |
| 59.52 MCNY | +53.83% | |
| 38.69 MCNY | +3.60% | |
| 37.35 MCNY | -13.05% | |
| 42.95 MCNY | -5.01% | |
| 45.22 MCNY | +178.20% | |
| 16.25 MCNY | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Vcanbio Cell & Gene Engineering Corp Stock analysis
Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock
Income Tax Expense of Vcanbio Cell & Gene Engineering Corp is 70.92 M CNY in 2025.
Income Tax Expense of Vcanbio Cell & Gene Engineering Corp changed from 46.59 M CNY to 70.92 M CNY, representing a 52.21% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Income Tax Expense Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.
Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.
Income Tax Expense's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's Vcanbio Cell & Gene Engineering Corp historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Vcanbio Cell & Gene Engineering Corp
All Key Metrics — Vcanbio Cell & Gene Engineering Corp
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth